OTC Mevacor Prospects Bleak In Light Of Short Post-Panel Review Period
This article was originally published in The Tan Sheet
Executive Summary
The timing of Merck's PDUFA deadline in relation to the recent advisory panel review of Mevacor Daily suggests FDA is unlikely to deem the OTC switch application "approvable.